Advertisement

Tumor Biology

, Volume 37, Issue 11, pp 14773–14778 | Cite as

Poly r(C) binding protein is post-transcriptionally repressed by MiR-490-3p to potentiate squamous cell carcinoma

  • Shan Xia
  • Zigang Zhao
  • Fang Xie
  • Jing He
  • Hengjin Li
Original Article

Abstract

Squamous cell skin carcinoma remains a leading cause of cancer-related mortality with a huge cost of treatment, necessitating discovery and validation of potent therapeutic targets. Poly r(C) binding protein 1 (PCBP1) has been previously shown to function as a tumor suppressor. Previous work has shown that PCBP1 expression is inversely correlated to maintenance of cancer stem cells in squamous cell skin carcinoma and prostate cancer, respectively. However, the precise mechanism that regulates PCBP1 expression has not been elucidated. Here, we show that loss of PCBP1 protein expression observed in CD34+ COLO-16 cells is orchestrated by translational silencing. Translational silencing is caused by targeting of PCBP1 mRNA by miR-490-3p. Exogenous manipulation of miR-490-3p levels can accordingly modulate PCBP1 protein expression, thus suggesting that miR-490-3p as a potential biomarker in squamous cell skin cancer with therapeutic benefits.

Keywords

Poly r(C) binding protein MiR-490-3p Potentiate squamous cell carcinoma 

Notes

Acknowledgments

None.

Compliance with ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Chinese PLA General Hospital, China and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained for by each patient included.

Conflict of interest

None

References

  1. 1.
    Neville JA, Welch E, Leffell DJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol. 2007;4:462–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Kim JE, Kim JH, Lee Y, Yang H, Heo YS, Bode AM, et al. Bakuchiol suppresses proliferation of skin cancer cells by directly targeting Hck, Blk, and p38 MAP kinase. Oncotarget. 2016. doi: 10.18632/oncotarget.7524.Google Scholar
  3. 3.
    Wolff T, Tai E, Miller T. Screening for skin cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;150:194–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Ridky TW. Nonmelanoma skin cancer. J Am Acad Dermatol. 2007;57:484–501.CrossRefPubMedGoogle Scholar
  5. 5.
    Guy Jr GP, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the U.S., 2002–2006 and 2007–2011. Am J Prev Med. 2015;48:183–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Wright TI, Spencer JM, Flowers FP. Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol. 2006;54:933–46.CrossRefPubMedGoogle Scholar
  7. 7.
    Chaudhury A, Hussey GS, Ray PS, Jin G, Fox PL, Howe PH. TGF-beta-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol. 2010;12:286–93.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Hussey GS, Chaudhury A, Dawson AE, Lindner DJ, Knudsen CR, Wilce MC, et al. Identification of an mRNP complex regulating tumorigenesis at the translational elongation step. Mol Cell. 2011;41:419–31.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Howley BV, Hussey GS, Link LA, Howe PH. Translational regulation of inhibin βA by TGFβ via the RNA-binding protein hnRNP E1 enhances the invasiveness of epithelial-to-mesenchymal transitioned cells. Oncogene. 2016;35(13):1725–35.CrossRefPubMedGoogle Scholar
  10. 10.
    Brown AS, Mohanty BK, Howe PH. Identification and characterization of an hnRNP E1 translational silencing motif. Nucleic Acids Res. 2016 Apr 11. pii: gkw241Google Scholar
  11. 11.
    Zhang ZZ, Shen ZY, Shen YY, Xu J, Zhao EH, Wang M, Wang CJ, Cao H. HOTAIR long noncoding RNA promotes gastric cancer metastasis through suppression of Poly r(C) Binding Protein (PCBP) 1. Mol Cancer Ther. 2015 Jan 22. pii: molcanther.0695.2014. [Epub ahead of print].Google Scholar
  12. 12.
    Zhang HY, Dou KF. PCBP1 is an important mediator of TGF-β-induced epithelial to mesenchymal transition in gall bladder cancer cell line GBC-SD. Mol Biol Rep. 2014;41:5519–24.CrossRefPubMedGoogle Scholar
  13. 13.
    Ghanem LR, Chatterji P, Liebhaber SA. Specific enrichment of the RNA-binding proteins PCBP1 and PCBP2 in chief cells of the murine gastric mucosa. Gene Expr Patterns. 2014;14:78–87.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Cho SJ, Jung YS, Chen X. Poly (C)-binding protein 1 regulates p63 expression through mRNA stability. PLoS One. 2013;8(8):e71724.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Shi Z, Zhang T, Long W, Wang X, Zhang X, Ling X, et al. Down-regulation of poly(rC)-binding protein 1 correlates with the malignant transformation of hydatidiform moles. Int J Gynecol Cancer. 2012;22:1125–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Lian WX, Yin RH, Kong XZ, Zhang T, Huang XH, Zheng WW, et al. THAP11, a novel binding protein of PCBP1, negatively regulates CD44 alternative splicing and cell invasion in a human hepatoma cell line. FEBS Lett. 2012;586:1431–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Wang H, Vardy LA, Tan CP, Loo JM, Guo K, Li J, et al. PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell. 2010;18:52–62.CrossRefPubMedGoogle Scholar
  18. 18.
    Song Q, Sheng W, Zhang X, Jiao S, Li F. ILEI drives epithelial to mesenchymal transition and metastatic progression in the lung cancer cell line A549. Tumour Biol. 2014;35:1377–82.CrossRefPubMedGoogle Scholar
  19. 19.
    Xue X, Wang X, Liu Y, Teng G, Wang Y, Zang X, et al. SchA-p85-FAK complex dictates isoform-specific activation of Akt2 and subsequent PCBP1-mediated post-transcriptional regulation of TGFβ-mediated epithelial to mesenchymal transition in human lung cancer cell line A549. Tumour Biol. 2014;35(8):7853–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Chen Q, Cai ZK, Chen YB, Gu M, Zheng DC, Zhou J, et al. Poly r(C) binding protein-1 is central to maintenance of cancer stem cells in prostate cancer cells. Cell Physiol Biochem. 2015;35(3):1052–61.CrossRefPubMedGoogle Scholar
  21. 21.
    Hu S, Wilson KD, Ghosh Z, Han L, Wang Y, Lan F, et al. MicroRNA-302 increases reprogramming efficiency via repression of NR2F2. Stem Cells. 2013;31:259–68.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Card DA, Hebbar PB, Li L, Trotter KW, Komatsu Y, Mishina Y, et al. Oct4/Sox2-regulated miR-302 targets cyclin D1 in human embryonic stem cells. Mol Cell Biol. 2008;28:6426–38.CrossRefPubMedGoogle Scholar
  23. 23.
    Zhang LY, Liu M, Li X, Tang H. miR-490-3p modulates cell growth and epithelial to mesenchymal transition of hepatocellular carcinoma cells by targeting endoplasmic reticulum-Golgi intermediate compartment protein 3 (ERGIC3). J Biol Chem. 2013;288:4035–47.CrossRefPubMedGoogle Scholar
  24. 24.
    Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, et al. Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. PLoS One. 2012;7:e34150.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Nakatani F, Ferracin M, Manara MC, Ventura S, Del Monaco V, Ferrari S, et al. miR-34a predicts survival of Ewing’s sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol. 2012;226:796–805.CrossRefPubMedGoogle Scholar
  26. 26.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.CrossRefPubMedGoogle Scholar
  27. 27.
    Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Can. 2006;6:259–69.CrossRefGoogle Scholar
  28. 28.
    Rachagani S, Macha MA, Heimann N, Seshacharyulu P, Haridas D, Chugh S, et al. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. Adv Drug Deliv Rev. 2015;81C:16–33.CrossRefGoogle Scholar
  29. 29.
    Alečković M, Kang Y. Regulation of cancer metastasis by cell-free miRNAs. Biochim Biophys Acta. 1855;2014:24–42.Google Scholar
  30. 30.
    Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007;67:2456–68.CrossRefPubMedGoogle Scholar
  32. 32.
    Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007;39:673–7.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Shan Xia
    • 1
    • 2
  • Zigang Zhao
    • 1
  • Fang Xie
    • 1
  • Jing He
    • 3
  • Hengjin Li
    • 1
  1. 1.Department of DermatologyChinese PLA General HospitalBeijingChina
  2. 2.Center for Disease Control and Prevention of Chengdu Military CommandChengduChina
  3. 3.Department of General SurgeryClinical Division of South Building, Chinese PLA General HospitalBeijingChina

Personalised recommendations